Senseonics, the maker of an implantable continuous glucose monitor device, has picked up $10 million in venture funding, according to a regulatory filing.
The company, based in Germantown, MD, didn't disclose its intentions for the funds in the SEC filing, though when it raised $20 million in venture capital in 2014, Senseonics said the money was earmarked for obtaining a CE mark and to start investigational device exemption trials in the U.S.
The Senseonics system includes a tiny sensor, external transmitters and a smartphone application. The sensor is implanted in the skin of the upper arm, and is designed to work for 6 months or longer before replacement.
To date, Senseonics has raised a total of at least $94 million and has investors that include Anthem Capital, Delphi Ventures and Healthcare Ventures.
In May, the company said it was teaming with Sweden-based Rubin Medical, an insulin pump distributor, for the distribution of its system in Sweden, Norway and Denmark. The company has said it expects to get a CE mark for its CGM device by the end of this year.
Senseonics isn't alone in the CGM market. Earlier this week, Dexcom ($DXCM) announced it is working with Google ($GOOG) to develop cheaper, miniaturized glucose monitors that would combine the search engine giant's electronics platform with Dexcom's technology.
- see the SEC filing
UPDATES to correct $10 million raised in latest round of funding